id
stringlengths 7
11
| context
stringlengths 24
527
| is_mult_event
bool 2
classes | annotations
list |
|---|---|---|---|
11435808_2 | Massive CBZ OD may produce a reversible encephalopathy that includes cortical hyperexcitability, a profound burst-suppression EEG pattern, and cranial nerve areflexia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"produce\"]], \"start\": [[19]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"Massive CBZ OD\"]], \"start\": [[0]], \"entity_id\": [\"T9\"], \"Dosage\": {\"text\": [[\"OD\"]], \"start\": [[12]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"CBZ\"]], \"start\": [[8]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"reversible encephalopathy that includes cortical hyperexcitability, a profound burst-suppression EEG pattern, and cranial nerve areflexia\"]], \"start\": [[29]], \"entity_id\": [\"T11\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[15]], \"entity_id\": [\"T14\"], \"value\": true}}"
}
]
}
] |
10755579_3 | This is the first report of a fluoxetine-related death in a child with a confirmed genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[41]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"fluoxetine\"]], \"start\": [[30]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"fluoxetine\"]], \"start\": [[30]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"death\"]], \"start\": [[49]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a child with a confirmed genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism\"]], \"start\": [[58]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"child\"]], \"start\": [[60]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism\"]], \"start\": [[83]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
16025424_2 | We report a case of reversible DKA and new-onset DM that developed in a demented patient who was treated with quetiapine for 14 days. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[57]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"quetiapine for 14 days\"]], \"start\": [[110]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"demented\"]], \"start\": [[72]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"quetiapine\"]], \"start\": [[110]], \"entity_id\": [\"T10\"]}, \"Duration\": {\"text\": [[\"14 days\"]], \"start\": [[125]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"demented patient\"]], \"start\": [[72]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"reversible DKA and new-onset DM\"]], \"start\": [[20]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
12811715_4 | We describe 3 cases of diphenhydramine-induced cardiac toxicity that were responsive to bicarbonate. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[39]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"diphenhydramine\"]], \"start\": [[23]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"diphenhydramine\"]], \"start\": [[23]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"cardiac toxicity\"]], \"start\": [[47]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"3 cases\"]], \"start\": [[12]], \"entity_id\": [\"T8\"], \"Population\": {\"text\": [[\"3\"]], \"start\": [[12]], \"entity_id\": [\"T9\"]}}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"responsive\"]], \"start\": [[74]], \"entity_id\": [\"T13\"]}, \"Subject\": {\"text\": [[\"3 cases\"]], \"start\": [[12]], \"entity_id\": [\"T8\"], \"Population\": {\"text\": [[\"3\"]], \"start\": [[12]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"bicarbonate\"]], \"start\": [[88]], \"entity_id\": [\"T11\"], \"Disorder\": {\"text\": [[\"diphenhydramine-induced cardiac toxicity\"]], \"start\": [[23]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"bicarbonate\"]], \"start\": [[88]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
17298107_1 | The patient's arthritis flared after the second infusion of infliximab, which was discontinued. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[31]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"arthritis flared\"]], \"start\": [[14]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"patient's\"]], \"start\": [[4]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"second infusion of infliximab\"]], \"start\": [[41]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"infliximab\"]], \"start\": [[60]], \"entity_id\": [\"T8\"]}, \"Route\": {\"text\": [[\"infusion\"]], \"start\": [[48]], \"entity_id\": [\"T7\"]}, \"Time_elapsed\": {\"text\": [[\"second\"]], \"start\": [[41]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
11077455_1 | CONCLUSION: Marked visual field constriction appears to be associated with vigabatrin therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[59]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Marked visual field constriction\"]], \"start\": [[12]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"vigabatrin therapy\"]], \"start\": [[75]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"vigabatrin\"]], \"start\": [[75]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
11215836_3 | Possible serotonin syndrome associated with clomipramine after withdrawal of clozapine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[57]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"serotonin syndrome associated with clomipramine\"]], \"start\": [[9]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"withdrawal of clozapine\"]], \"start\": [[63]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"clozapine\"], [\"clomipramine\"]], \"start\": [[77], [44]], \"entity_id\": [\"T8\", \"T9\"]}}, \"Speculated\": {\"text\": [[\"Possible\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
1295628_2 | A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; Tegretol) used against benign Rolandic epilepsy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[21]], \"entity_id\": [\"T19\"]}, \"Subject\": {\"text\": [[\"A 14-year-old female\"]], \"start\": [[0]], \"entity_id\": [\"T16\"], \"Age\": {\"text\": [[\"14-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T20\"]}, \"Gender\": {\"text\": [[\"female\"]], \"start\": [[14]], \"entity_id\": [\"T21\"]}}, \"Effect\": {\"text\": [[\"systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and positive anti-nuclear antibody (ANA)\"]], \"start\": [[31]], \"entity_id\": [\"T17\"]}, \"Treatment\": {\"text\": [[\"administration of carbamazepine (CBZ; Tegretol) used against benign Rolandic epilepsy\"]], \"start\": [[162]], \"entity_id\": [\"T18\"], \"Drug\": {\"text\": [[\"carbamazepine\"]], \"start\": [[180]], \"entity_id\": [\"T22\"]}, \"Disorder\": {\"text\": [[\"benign Rolandic epilepsy\"]], \"start\": [[223]], \"entity_id\": [\"T23\"]}}}"
}
]
}
] |
6236730_2 | There was a clear relationship between restarting the Accutane and recurrence of the transient myopia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"a clear relationship\"]], \"start\": [[10]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Accutane\"]], \"start\": [[54]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Accutane\"]], \"start\": [[54]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"recurrence of the transient myopia\"]], \"start\": [[67]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
7718983_3 | Graves' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[59]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Graves' hyperthyroidism following transient thyrotoxicosis\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"interferon therapy\"]], \"start\": [[66]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"interferon therapy\"]], \"start\": [[66]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"chronic hepatitis type C\"]], \"start\": [[89]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
1445134_4 | Masculinization of a female fetus occurred in 5 of 39 (12.8%) exposed to norethisterone; all were cases of clitoral hypertrophy not requiring surgical treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"exposed\"]], \"start\": [[62]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"Masculinization of a female fetus\", \"clitoral hypertrophy\"]], \"start\": [[0, 107]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"5 of 39 (12.8%)\"]], \"start\": [[46]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"5 of 39 (12.8%)\"]], \"start\": [[46]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"norethisterone\"]], \"start\": [[73]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"norethisterone\"]], \"start\": [[73]], \"entity_id\": [\"T10\"]}}, \"Severity\": {\"text\": [[\"not requiring surgical treatment\"]], \"start\": [[128]], \"entity_id\": [\"T11\"], \"value\": \"Low\"}}"
}
]
}
] |
9161656_16 | She continued taking verapamil for 6 months, then, on her own, stopped all medications including the sustained-release verapamil, and her asthma symptoms disappeared. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"disappeared\"]], \"start\": [[154]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"She\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Gender\": {\"text\": [[\"She\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"continued taking verapamil for 6 months, then, on her own, stopped all medications including the sustained-release verapamil\"]], \"start\": [[4]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"asthma\"]], \"start\": [[138]], \"entity_id\": [\"T3\"]}, \"Drug\": {\"text\": [[\"verapamil\"]], \"start\": [[21]], \"entity_id\": [\"T8\"]}, \"Duration\": {\"text\": [[\"for 6 months\"]], \"start\": [[31]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
9311175_2 | Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"reactions\"]], \"start\": [[131]], \"entity_id\": [\"T23\"]}, \"Treatment\": {\"text\": [[\"cisplatin\", \"involving intrahepatic artery infusion\"]], \"start\": [[144, 160]], \"entity_id\": [\"T26\"], \"Drug\": {\"text\": [[\"cisplatin\"]], \"start\": [[144]], \"entity_id\": [\"T33\"]}, \"Disorder\": {\"text\": [[\"ovarian cancer\"]], \"start\": [[18]], \"entity_id\": [\"T32\"]}, \"Route\": {\"text\": [[\"intrahepatic artery infusion\"]], \"start\": [[170]], \"entity_id\": [\"T27\"]}}, \"Subject\": {\"text\": [[\"one\"]], \"start\": [[155]], \"entity_id\": [\"T22\"]}, \"Effect\": {\"text\": [[\"manifested general erythema, dyspnea, and hypotension\"]], \"start\": [[200]], \"entity_id\": [\"T24\"]}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"reactions\"]], \"start\": [[131]], \"entity_id\": [\"T23\"]}, \"Subject\": {\"text\": [[\"the other\"]], \"start\": [[255]], \"entity_id\": [\"T34\"]}, \"Treatment\": {\"text\": [[\"cisplatin\", \"involving intravenous infusion\"]], \"start\": [[144, 266]], \"entity_id\": [\"T31\"], \"Drug\": {\"text\": [[\"cisplatin\"]], \"start\": [[144]], \"entity_id\": [\"T25\"]}, \"Route\": {\"text\": [[\"intravenous infusion\"]], \"start\": [[276]], \"entity_id\": [\"T28\"]}}, \"Effect\": {\"text\": [[\"manifested abdominal pain, general erythema, and fever\"]], \"start\": [[298]], \"entity_id\": [\"T30\"]}}"
}
]
}
] |
12324937_2 | CONCLUSION: There are only a few confirmed cases of gemcitabine-associated HUS despite the widespread use of the drug. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[64]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"gemcitabine\"]], \"start\": [[52]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"gemcitabine\"]], \"start\": [[52]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"HUS\"]], \"start\": [[75]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"few\"]], \"start\": [[29]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
19365885_3 | In these patients, long-acting octreotide may trigger serious hypoglycemia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"trigger\"]], \"start\": [[46]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"these patients\"]], \"start\": [[3]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"long-acting octreotide\"]], \"start\": [[19]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"octreotide\"]], \"start\": [[31]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"serious hypoglycemia\"]], \"start\": [[54]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
1722991_1 | Usefulness of antiplatelet drugs in the management of heparin-associated thrombocytopenia and thrombosis. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[62]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"heparin\"]], \"start\": [[54]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"heparin\"]], \"start\": [[54]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"thrombocytopenia and thrombosis\"]], \"start\": [[73]], \"entity_id\": [\"T9\"]}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"Usefulness\"]], \"start\": [[0]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"antiplatelet drugs\"]], \"start\": [[14]], \"entity_id\": [\"T14\"], \"Disorder\": {\"text\": [[\"heparin-associated thrombocytopenia and thrombosis\"]], \"start\": [[54]], \"entity_id\": [\"T15\"]}, \"Drug\": {\"text\": [[\"antiplatelet drugs\"]], \"start\": [[14]], \"entity_id\": [\"T13\"]}}}"
}
]
}
] |
17039658_1 | An intertrigo-like eruption from pegylated liposomal doxorubicin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"from\"]], \"start\": [[28]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"pegylated liposomal doxorubicin\"]], \"start\": [[33]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"doxorubicin\"]], \"start\": [[53]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"intertrigo-like eruption\"]], \"start\": [[3]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
14514135_2 | We report a case of NEH masquerading as cutaneous vasculitis in a woman receiving cyclophosphamide for lupus nephritis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[61]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"cyclophosphamide\"]], \"start\": [[82]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"cyclophosphamide\"]], \"start\": [[82]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"lupus nephritis.\"]], \"start\": [[103]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"NEH masquerading as cutaneous vasculitis\"]], \"start\": [[20]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a woman\", \"for lupus nephritis\"]], \"start\": [[64, 99]], \"entity_id\": [\"T5\"], \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[66]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
12621956_1 | The diagnosis of hypothermia was delayed until it was apparent for several days but resolved with the discontinuation of risperidone and continuation of clozapine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"resolved\"]], \"start\": [[84]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"discontinuation of risperidone and continuation of clozapine\"]], \"start\": [[102]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"clozapine\"], [\"risperidone\"]], \"start\": [[153], [121]], \"entity_id\": [\"T6\", \"T7\"]}, \"Disorder\": {\"text\": [[\"hypothermia\"]], \"start\": [[17]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
10048291_2 | Unaccountable severe hypercalcemia in a patient treated for hypoparathyroidism with dihydrotachysterol. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[48]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"dihydrotachysterol\"]], \"start\": [[84]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"hypoparathyroidism\"]], \"start\": [[60]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"dihydrotachysterol\"]], \"start\": [[84]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"Unaccountable severe hypercalcemia\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"patient\"]], \"start\": [[40]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
11022272_1 | Anaphylaxis to calcitonin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"to\"]], \"start\": [[12]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Anaphylaxis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"calcitonin\"]], \"start\": [[15]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"calcitonin\"]], \"start\": [[15]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
19764104_1 | However, he developed acute renal failure, hyperkalemia, and hyperuricemia 30 d after receiving the sorafenib treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[12]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"he\"]], \"start\": [[9]], \"entity_id\": [\"T8\"], \"Gender\": {\"text\": [[\"he\"]], \"start\": [[9]], \"entity_id\": [\"T11\"]}}, \"Treatment\": {\"text\": [[\"sorafenib\"]], \"start\": [[100]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"sorafenib\"]], \"start\": [[100]], \"entity_id\": [\"T12\"]}, \"Time_elapsed\": {\"text\": [[\"30 d\"]], \"start\": [[75]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"acute renal failure, hyperkalemia, and hyperuricemia\"]], \"start\": [[22]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
17983451_1 | Mycobacterium marinum infection complicating Crohn's disease, treated with infliximab. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[62]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"infliximab\"]], \"start\": [[75]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"Mycobacterium marinum infection complicating Crohn's disease\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"infliximab\"]], \"start\": [[75]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
16649344_2 | Current immunosuppressive therapies are effective but can be associated with significant adverse reactions. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[61]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Current immunosuppressive therapies\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"immunosuppressive\"]], \"start\": [[8]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"significant adverse reactions.\"]], \"start\": [[77]], \"entity_id\": [\"T7\"]}, \"Speculated\": {\"text\": [[\"can be\"]], \"start\": [[54]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
1977935_4 | This report describes the first association (exclusive of drug overdose) of symptomatic torsades de pointes occurring with the use of terfenadine in a patient who was taking the recommended prescribed dose of this drug in addition to cefaclor, ketoconazole, and medroxyprogesterone. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurring\"]], \"start\": [[108]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"terfenadine\", \"taking the recommended prescribed dose of this drug in addition to cefaclor, ketoconazole, and medroxyprogesterone\"]], \"start\": [[134, 167]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"cefaclor\"], [\"ketoconazole\"], [\"medroxyprogesterone\"], [\"terfenadine\"]], \"start\": [[234], [244], [262], [134]], \"entity_id\": [\"T13\", \"T14\", \"T15\", \"T16\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"addition\"]], \"start\": [[222]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"terfenadine\"], [\"cefaclor\"], [\"ketoconazole\"], [\"medroxyprogesterone\"]], \"start\": [[134], [234], [244], [262]], \"entity_id\": [\"T16\", \"T13\", \"T14\", \"T15\"]}}]}, \"Effect\": {\"text\": [[\"symptomatic torsades de pointes\"]], \"start\": [[76]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[149]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
9232614_2 | Tamoxifen is suggested to be carcinogenic both through direct genotoxic and epigenetic mechanisms. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"suggested\"]], \"start\": [[13]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Tamoxifen\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Tamoxifen\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"carcinogenic both through direct genotoxic and epigenetic mechanisms\"]], \"start\": [[29]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
14632592_3 | DISCUSSION: Colchicine, the most important drug in treatment of FMF, can cause myopathy in patients with impaired renal and hepatic function. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[73]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Colchicine\"]], \"start\": [[12]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Colchicine\"]], \"start\": [[12]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"FMF\"]], \"start\": [[64]], \"entity_id\": [\"T4\"]}}, \"Effect\": {\"text\": [[\"myopathy\"]], \"start\": [[79]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"patients with impaired renal and hepatic function\"]], \"start\": [[91]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"impaired renal and hepatic function\"]], \"start\": [[105]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
7673653_4 | In the presented case fluvoxamine-induced akathisia in an OCD patient was partially resistant to the anticholinergic agent biperiden, and was successfully treated with the 5-HT2A/5-HT2C antagonist mianserin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[155]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"fluvoxamine-induced akathisia in an OCD patient\"]], \"start\": [[22]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"5-HT2A/5-HT2C antagonist mianserin\"]], \"start\": [[172]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"akathisia\"], [\"OCD\"]], \"start\": [[42], [58]], \"entity_id\": [\"T8\", \"T9\"]}, \"Drug\": {\"text\": [[\"mianserin\"]], \"start\": [[197]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
16225183_7 | SUBSEQUENT COURSE: The nephrosis resolved almost completely once the interferon was stopped and after immunosuppressive treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"resolved\"]], \"start\": [[33]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"interferon was stopped and after immunosuppressive treatment\"]], \"start\": [[69]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"interferon\"], [\"immunosuppressive\"]], \"start\": [[69], [102]], \"entity_id\": [\"T9\", \"T10\"]}, \"Disorder\": {\"text\": [[\"nephrosis\"]], \"start\": [[23]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
8149366_1 | In two patients, apomorphine remained effective in the morning, but increased the intensity of the dyskinesias in the afternoon. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"increased\"]], \"start\": [[68]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"In two patients\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[3]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"apomorphine\"]], \"start\": [[17]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"apomorphine\"]], \"start\": [[17]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"intensity of the dyskinesias in the afternoon\"]], \"start\": [[82]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
18079582_2 | Transient asymptomatic bradycardia in patients on infusional 5-fluorouracil. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"on\"]], \"start\": [[47]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"infusional 5-fluorouracil.\"]], \"start\": [[50]], \"entity_id\": [\"T4\"], \"Route\": {\"text\": [[\"infusional\"]], \"start\": [[50]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"5-fluorouracil\"]], \"start\": [[61]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"Transient asymptomatic bradycardia\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[38]], \"entity_id\": [\"T6\"]}, \"Severity\": {\"text\": [[\"Transient\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"value\": \"Low\"}}"
}
]
}
] |
25515435_6 | In 2006, he was diagnosed with deep vein thrombosis and pulmonary embolism and was started on warfarin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"started\"]], \"start\": [[83]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"he\"]], \"start\": [[9]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"he\"]], \"start\": [[9]], \"entity_id\": [\"T10\"]}}, \"Treatment\": {\"text\": [[\"warfarin\"]], \"start\": [[94]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"deep vein thrombosis and pulmonary embolism\"]], \"start\": [[31]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"warfarin\"]], \"start\": [[94]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
17026827_1 | Scleritis complicating zoledronic acid infusion. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complicating\"]], \"start\": [[10]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Scleritis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"zoledronic acid infusion\"]], \"start\": [[23]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"zoledronic acid\"]], \"start\": [[23]], \"entity_id\": [\"T6\"]}, \"Route\": {\"text\": [[\"infusion\"]], \"start\": [[39]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
10467499_1 | A 22-year-old black man developed fever, chills, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting minocycline therapy for acne. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[24]], \"entity_id\": [\"T12\"]}, \"Effect\": {\"text\": [[\"fever, chills, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption\"]], \"start\": [[34]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"minocycline therapy\"]], \"start\": [[165]], \"entity_id\": [\"T13\"], \"Disorder\": {\"text\": [[\"acne\"]], \"start\": [[189]], \"entity_id\": [\"T18\"]}, \"Drug\": {\"text\": [[\"minocycline\"]], \"start\": [[165]], \"entity_id\": [\"T19\"]}, \"Time_elapsed\": {\"text\": [[\"3 weeks\"]], \"start\": [[142]], \"entity_id\": [\"T20\"]}}, \"Subject\": {\"text\": [[\"A 22-year-old black man\"]], \"start\": [[0]], \"entity_id\": [\"T14\"], \"Age\": {\"text\": [[\"22-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T15\"]}, \"Race\": {\"text\": [[\"black\"]], \"start\": [[14]], \"entity_id\": [\"T16\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[20]], \"entity_id\": [\"T17\"]}}}"
}
]
}
] |
12221670_4 | Ticlopidine-induced aplastic anemia: two new case reports, review, and meta-analysis of 55 additional cases. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[12]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Ticlopidine\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Ticlopidine\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"aplastic anemia\"]], \"start\": [[20]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
11757641_2 | This is the second report of acute lung injury and diffuse alveolar damage caused by mefloquine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[75]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"acute lung injury and diffuse alveolar damage\"]], \"start\": [[29]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"mefloquine\"]], \"start\": [[85]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"mefloquine\"]], \"start\": [[85]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
480917_1 | A case of Erythema Multiforme Bullosum in patient of lepromatous leprosy with pulmonary tuberculosis due to Rifampicin is described. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due to\"]], \"start\": [[101]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Erythema Multiforme Bullosum\"]], \"start\": [[10]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"patient of lepromatous leprosy with pulmonary tuberculosis\"]], \"start\": [[42]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Rifampicin\"]], \"start\": [[108]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"pulmonary tuberculosis\"], [\"lepromatous leprosy\"]], \"start\": [[78], [53]], \"entity_id\": [\"T5\", \"T8\"]}, \"Drug\": {\"text\": [[\"Rifampicin\"]], \"start\": [[108]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
7661076_2 | Life-threatening alterations in heart rate after the use of adenosine in atrial flutter. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[43]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"adenosine\"]], \"start\": [[60]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"adenosine\"]], \"start\": [[60]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Life-threatening alterations in heart rate\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Severity\": {\"text\": [[\"Life-threatening\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"value\": \"Medium\"}}"
}
]
}
] |
9719245_4 | We report a case of pancytopenia in a 23-year-old man with Crohn's disease who was treated with 5-aminosalicylic acid (Pentasa; Nisshin, Tokyo, Japan) 3.0 g/day. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treated with\"]], \"start\": [[83]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a 23-year-old man with Crohn's disease\"]], \"start\": [[36]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"23-year-old\"]], \"start\": [[38]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[50]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"pancytopenia\"]], \"start\": [[20]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"5-aminosalicylic acid (Pentasa; Nisshin, Tokyo, Japan) 3.0 g/day\"]], \"start\": [[96]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"Crohn's disease\"]], \"start\": [[59]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"5-aminosalicylic acid\"], [\"Pentasa\"]], \"start\": [[96], [119]], \"entity_id\": [\"T11\", \"T12\"]}, \"Dosage\": {\"text\": [[\"3.0 g/day\"]], \"start\": [[151]], \"entity_id\": [\"T13\"]}}}"
}
]
}
] |
9169264_2 | The ampicillin rash occurring in cases of infectious mononucleosis is well documented. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurring\"]], \"start\": [[20]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"The ampicillin rash\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"ampicillin\"]], \"start\": [[4]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"ampicillin\"]], \"start\": [[4]], \"entity_id\": [\"T6\"]}, \"Disorder\": {\"text\": [[\"infectious mononucleosis\"]], \"start\": [[42]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
16204273_1 | The major side effect of infliximab is infection. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"of\"]], \"start\": [[22]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"infliximab\"]], \"start\": [[25]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"infliximab\"]], \"start\": [[25]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"infection\"]], \"start\": [[39]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
11545487_1 | An asymptomatic HIV-infected woman experienced right-sided renal colicky pain during treatment with indinavir. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"experienced\"]], \"start\": [[35]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"An asymptomatic HIV-infected woman\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[29]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"right-sided renal colicky pain\"]], \"start\": [[47]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"indinavir\"]], \"start\": [[100]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"indinavir\"]], \"start\": [[100]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"HIV\"]], \"start\": [[16]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
6233326_3 | The case resembles two previously reported cases of optic neuropathy which occurred in patients with Wilson's disease who were receiving penicillamine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurred\"]], \"start\": [[75]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"optic neuropathy\"]], \"start\": [[52]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"patients with Wilson's disease\"]], \"start\": [[87]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"penicillamine\"]], \"start\": [[137]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"penicillamine\"]], \"start\": [[137]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"Wilson's disease\"]], \"start\": [[101]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
1743388_1 | Cutaneous ulceration: an unusual complication of intravenous pentamidine therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complication\"]], \"start\": [[33]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Cutaneous ulceration\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"intravenous pentamidine\"]], \"start\": [[49]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"pentamidine\"]], \"start\": [[61]], \"entity_id\": [\"T6\"]}, \"Route\": {\"text\": [[\"intravenous\"]], \"start\": [[49]], \"entity_id\": [\"T7\"]}}, \"Speculated\": {\"text\": [[\"unusual\"]], \"start\": [[25]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
8222875_3 | Pulmonary hemorrhage is an uncommon feature in the HUS, and seems to appear especially in the HUS associated with MMC therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"appear\"]], \"start\": [[69]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"Pulmonary hemorrhage\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"MMC\"]], \"start\": [[114]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"MMC\"]], \"start\": [[114]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
9017913_1 | Immunosuppression elicited by the extensive administration of prednisolone was suspected for the initiation of the generalized mite infestation. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"generalized\"]], \"start\": [[115]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"extensive administration of prednisolone\"]], \"start\": [[34]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"prednisolone\"]], \"start\": [[62]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"mite infestation\"]], \"start\": [[127]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
6414095_4 | The episode appeared to have been precipitated by toxicity due to ingestion of a large amount of phenytoin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[59]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"a large amount of phenytoin.\"]], \"start\": [[79]], \"entity_id\": [\"T5\"], \"Route\": {\"text\": [[\"ingestion\"]], \"start\": [[66]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"phenytoin\"]], \"start\": [[97]], \"entity_id\": [\"T8\"]}, \"Dosage\": {\"text\": [[\"large amount\"]], \"start\": [[81]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"The episode appeared to have been precipitated by toxicity\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
3370103_1 | Cardiopulmonary arrest following intravenous phenytoin loading. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[23]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Cardiopulmonary arrest\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"intravenous phenytoin loading\"]], \"start\": [[33]], \"entity_id\": [\"T5\"], \"Route\": {\"text\": [[\"intravenous\"]], \"start\": [[33]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"phenytoin\"]], \"start\": [[45]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
11487721_1 | Although taxol has shown significant activity in advanced ovarian cancer, peripheral neuropathy is likely to become the major dose-limiting toxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"toxicity\"]], \"start\": [[140]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"taxol\"]], \"start\": [[9]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"taxol\"]], \"start\": [[9]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"peripheral neuropathy\"]], \"start\": [[74]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
19017039_2 | Syringotropic hypersensitivity reaction associated with infliximab and leflunomide combination therapy in a child with psoriatic arthritis. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[40]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Syringotropic hypersensitivity reaction\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"infliximab and leflunomide combination therapy\"]], \"start\": [[56]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"infliximab\"], [\"leflunomide\"]], \"start\": [[56], [71]], \"entity_id\": [\"T10\", \"T11\"]}, \"Disorder\": {\"text\": [[\"psoriatic arthritis\"]], \"start\": [[119]], \"entity_id\": [\"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combination\"]], \"start\": [[83]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"leflunomide\"], [\"infliximab\"]], \"start\": [[71], [56]], \"entity_id\": [\"T11\", \"T10\"]}}]}, \"Subject\": {\"text\": [[\"a child with psoriatic arthritis\"]], \"start\": [[106]], \"entity_id\": [\"T7\"], \"Age\": {\"text\": [[\"child\"]], \"start\": [[108]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
3438585_5 | Corticosteroid therapy was continued for 8 months since there was still improvement of pulmonary function studies. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"improvement\"]], \"start\": [[72]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Corticosteroid\", \"for 8 months\"]], \"start\": [[0, 37]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"pulmonary function\"]], \"start\": [[87]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"Corticosteroid\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Duration\": {\"text\": [[\"for 8 months\"]], \"start\": [[37]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
19567656_3 | OBJECTIVE: To describe a case of sertraline-induced rhabdomyolysis in an elderly patient with dementia and comorbidities. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[44]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"sertraline\"]], \"start\": [[33]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"comorbidities\"], [\"dementia\"]], \"start\": [[107], [94]], \"entity_id\": [\"T9\", \"T11\"]}, \"Drug\": {\"text\": [[\"sertraline\"]], \"start\": [[33]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"rhabdomyolysis\"]], \"start\": [[52]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"an elderly patient with dementia and comorbidities\"]], \"start\": [[70]], \"entity_id\": [\"T7\"], \"Age\": {\"text\": [[\"elderly\"]], \"start\": [[73]], \"entity_id\": [\"T3\"]}}}"
}
]
}
] |
15028964_3 | Beyond the predictable pharmacokinetic drug-drug interaction requiring a significant warfarin dose reduction, the iodine-rich amiodarone affects the thyroid gland, causing overt hypothyroidism or thyrotoxicosis in 14%-18% of cases. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"causing\"]], \"start\": [[164]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"iodine-rich amiodarone\"]], \"start\": [[114]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"iodine-rich amiodarone\"]], \"start\": [[114]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"overt hypothyroidism or thyrotoxicosis\"]], \"start\": [[172]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
12086549_4 | Toxic epidermal necrolysis associated with interleukin-2. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[27]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Toxic epidermal necrolysis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"interleukin-2\"]], \"start\": [[43]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"interleukin-2\"]], \"start\": [[43]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
9840249_2 | The pulmonary toxicity of gold salts is an uncommon cause of life-threatening respiratory failure. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[52]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"pulmonary toxicity\", \"life-threatening respiratory failure\"]], \"start\": [[4, 61]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"gold salts\"]], \"start\": [[26]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"gold\"]], \"start\": [[26]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
15383642_14 | With its characteristics, tizanidine has the potential to compromise hemodynamic stability during concomitant angiotensin-converting enzyme inhibitor use. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"compromise\"]], \"start\": [[58]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"tizanidine\", \"during concomitant angiotensin-converting enzyme inhibitor use\"]], \"start\": [[26, 91]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"tizanidine\"], [\"angiotensin-converting enzyme inhibitor\"]], \"start\": [[26], [110]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"concomitant\"]], \"start\": [[98]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"tizanidine\"], [\"angiotensin-converting enzyme inhibitor\"]], \"start\": [[26], [110]], \"entity_id\": [\"T10\", \"T11\"]}}]}, \"Effect\": {\"text\": [[\"compromise hemodynamic stability\"]], \"start\": [[58]], \"entity_id\": [\"T9\"]}, \"Speculated\": {\"text\": [[\"potential\"]], \"start\": [[45]], \"entity_id\": [\"T13\"], \"value\": true}}"
}
]
}
] |
17060191_1 | Premature closure of the ductus arteriosus: variable response among monozygotic twins after in utero exposure to indomethacin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[86]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"monozygotic twins\"]], \"start\": [[68]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"in utero exposure to indomethacin\"]], \"start\": [[92]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"indomethacin\"]], \"start\": [[113]], \"entity_id\": [\"T9\"]}, \"Route\": {\"text\": [[\"in utero exposure\"]], \"start\": [[92]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"Premature closure of the ductus arteriosus\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
8239963_2 | Possible mechanisms by which clonidine decreases spasticity are described, probable mechanisms of induced bradycardia are reviewed, and specific treatment recommendations for the use of clonidine in spinal cord injured patients are presented. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[98]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"clonidine\"]], \"start\": [[29]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"clonidine\"]], \"start\": [[29]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"spinal cord injured\"]], \"start\": [[199]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"bradycardia\"]], \"start\": [[106]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
10475726_3 | This is the first report of a possible association between an acute cardiovascular event and venlafaxine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"association\"]], \"start\": [[39]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"an acute cardiovascular event\"]], \"start\": [[59]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"venlafaxine\"]], \"start\": [[93]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"venlafaxine\"]], \"start\": [[93]], \"entity_id\": [\"T6\"]}}, \"Speculated\": {\"text\": [[\"possible\"]], \"start\": [[30]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
6830388_1 | Since early symptoms of the toxic effects of theophylline can mimic peptic ulcer disease, cimetidine might be prescribed for the gastrointestinal symptoms with subsequent worsening of theophylline poisoning. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"prescribed\"]], \"start\": [[110]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"cimetidine\"]], \"start\": [[90]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"gastrointestinal symptoms\"]], \"start\": [[129]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"cimetidine\"]], \"start\": [[90]], \"entity_id\": [\"T7\"]}}, \"Speculated\": {\"text\": [[\"might\"]], \"start\": [[101]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
9256906_1 | Acute renal failure in a patient receiving treatment with suramin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[20]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Acute renal failure\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[23]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"suramin\"]], \"start\": [[58]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"suramin\"]], \"start\": [[58]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
6540393_1 | A further case of anaphylactoid reaction to methylprednisolone is reported. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"to\"]], \"start\": [[41]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"anaphylactoid reaction\"]], \"start\": [[18]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"methylprednisolone\"]], \"start\": [[44]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"methylprednisolone\"]], \"start\": [[44]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
8222875_2 | Pulmonary hemorrhage as a clinical manifestation of hemolytic-uremic syndrome associated with mitomycin C therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[78]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Pulmonary hemorrhage\", \"hemolytic-uremic syndrome\"]], \"start\": [[0, 52]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"mitomycin C therapy\"]], \"start\": [[94]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"mitomycin C\"]], \"start\": [[94]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
4054170_3 | EEG abnormalities were observed in two of the nine children during chlorambucil therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"observed\"]], \"start\": [[23]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"chlorambucil\"]], \"start\": [[67]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"chlorambucil\"]], \"start\": [[67]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"EEG abnormalities\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"two of the nine children\"]], \"start\": [[35]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"two of the nine\"]], \"start\": [[35]], \"entity_id\": [\"T7\"]}, \"Age\": {\"text\": [[\"children\"]], \"start\": [[51]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
9111724_1 | Discontinuation of the itraconazole caused resolution of the drug eruption. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[36]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"itraconazole\"]], \"start\": [[23]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"itraconazole\"]], \"start\": [[23]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"drug eruption\"]], \"start\": [[61]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
19307676_2 | The addition of intrathecal methotrexate to treatment protocols has increased survival rates in children with acute lymphoblastic leukemia but is also associated with varying degrees of neurotoxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[151]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"varying degrees of neurotoxicity\"]], \"start\": [[167]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"The addition of intrathecal methotrexate to treatment protocols\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[28]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"acute lymphoblastic leukemia\"]], \"start\": [[110]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"in children with acute lymphoblastic leukemia\"]], \"start\": [[93]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"children\"]], \"start\": [[96]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
10473079_1 | We conclude that the presence of this metabolic defect combined with topical 5-FU (a drug demonstrating a narrow therapeutic index) results in the unusual presentation of life-threatening toxicity after treatment with a topical drug. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"results in\"]], \"start\": [[132]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"unusual presentation of life-threatening toxicity\"]], \"start\": [[147]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"topical 5-FU (a drug demonstrating a narrow therapeutic index)\"]], \"start\": [[69]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"5-FU\"]], \"start\": [[77]], \"entity_id\": [\"T9\"]}, \"Route\": {\"text\": [[\"topical\"]], \"start\": [[69]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"this metabolic defect\"]], \"start\": [[33]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"metabolic defect\"]], \"start\": [[38]], \"entity_id\": [\"T6\"]}}, \"Severity\": {\"text\": [[\"life-threatening\"]], \"start\": [[171]], \"entity_id\": [\"T8\"], \"value\": \"Medium\"}}"
}
]
}
] |
6958210_1 | Six patients with rheumatoid arthritis developed a syndrome resembling lupus erythematosus while being treated with penicillamine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[39]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"Six patients with rheumatoid arthritis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"Six\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"syndrome resembling lupus erythematosus\"]], \"start\": [[51]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"penicillamine\"]], \"start\": [[116]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"penicillamine\"]], \"start\": [[116]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"rheumatoid arthritis\"]], \"start\": [[18]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
12590235_3 | This case highlights the need to monitor liver enzymes in patients treated with 6-TG and identifies the need for additional research focused on the mechanism of thiopurine-induced hepatic injury. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[172]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"thiopurine\"]], \"start\": [[161]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"thiopurine\"]], \"start\": [[161]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"hepatic injury\"]], \"start\": [[180]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"patients treated with 6-TG\"]], \"start\": [[58]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
9347384_2 | During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[71]], \"entity_id\": [\"T19\"]}, \"Subject\": {\"text\": [[\"four out of the seven patients\"]], \"start\": [[40]], \"entity_id\": [\"T18\"], \"Population\": {\"text\": [[\"four out of the seven\"]], \"start\": [[40]], \"entity_id\": [\"T21\"]}}, \"Treatment\": {\"text\": [[\"During clarithromycin coadministration\", \"carbamazepine\"]], \"start\": [[0, 118]], \"entity_id\": [\"T17\"], \"Time_elapsed\": {\"text\": [[\"During\"]], \"start\": [[0]], \"entity_id\": [\"T22\"]}, \"Drug\": {\"text\": [[\"clarithromycin\"], [\"carbamazepine\"]], \"start\": [[7], [118]], \"entity_id\": [\"T23\", \"T25\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"coadministration\"]], \"start\": [[22]], \"entity_id\": [\"T24\"]}, \"Drug\": {\"text\": [[\"clarithromycin\"], [\"carbamazepine\"]], \"start\": [[7], [118]], \"entity_id\": [\"T23\", \"T25\"]}}]}, \"Effect\": {\"text\": [[\"moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia\"]], \"start\": [[81]], \"entity_id\": [\"T20\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[93]], \"entity_id\": [\"T29\"], \"value\": \"Medium\"}}"
},
{
"event_id": "E3",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E3\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"resolved\"]], \"start\": [[182]], \"entity_id\": [\"T27\"]}, \"Treatment\": {\"text\": [[\"5 days after clarithromycin discontinuation\"]], \"start\": [[198]], \"entity_id\": [\"T28\"], \"Drug\": {\"text\": [[\"clarithromycin\"]], \"start\": [[211]], \"entity_id\": [\"T30\"]}, \"Disorder\": {\"text\": [[\"moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia\"]], \"start\": [[81]], \"entity_id\": [\"T31\"]}}}"
}
]
}
] |
10099659_2 | 5-Fluorouracil (5-FU) is an analogue of pyrimidine nucleosides that is widely used in the treatment of head and neck, breast, ovarian, and colon cancer. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"used\"]], \"start\": [[78]], \"entity_id\": [\"T16\"]}, \"Treatment\": {\"text\": [[\"5-Fluorouracil (5-FU) is an analogue of pyrimidine nucleosides\"]], \"start\": [[0]], \"entity_id\": [\"T15\"], \"Drug\": {\"text\": [[\"5-Fluorouracil (5-FU)\"]], \"start\": [[0]], \"entity_id\": [\"T17\"]}, \"Disorder\": {\"text\": [[\"head and neck, breast, ovarian, and colon cancer\"]], \"start\": [[103]], \"entity_id\": [\"T18\"]}}}"
}
]
}
] |
19782276_1 | Fulminant fatal cardiotoxicity following cyclophosphamide therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[31]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"cyclophosphamide\"]], \"start\": [[41]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"cyclophosphamide\"]], \"start\": [[41]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Fulminant fatal cardiotoxicity\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
15383642_11 | The reaction in our patient appeared after tizanidine initiation and improved after both lisinopril and tizanidine were discontinued. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[37]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"tizanidine initiation\"]], \"start\": [[43]], \"entity_id\": [\"T17\"], \"Drug\": {\"text\": [[\"tizanidine\"]], \"start\": [[43]], \"entity_id\": [\"T18\"]}}, \"Subject\": {\"text\": [[\"patient\"]], \"start\": [[20]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"reaction\"]], \"start\": [[4]], \"entity_id\": [\"T11\"]}}"
},
{
"event_id": "E3",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E3\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"improved\"]], \"start\": [[69]], \"entity_id\": [\"T20\"]}, \"Subject\": {\"text\": [[\"patient\"]], \"start\": [[20]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"both lisinopril and tizanidine\"]], \"start\": [[84]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"reaction\"]], \"start\": [[4]], \"entity_id\": [\"T19\"]}, \"Drug\": {\"text\": [[\"lisinopril\"], [\"tizanidine\"]], \"start\": [[89], [104]], \"entity_id\": [\"T13\", \"T14\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"both\"]], \"start\": [[84]], \"entity_id\": [\"T15\"]}, \"Drug\": {\"text\": [[\"lisinopril\"], [\"tizanidine\"]], \"start\": [[89], [104]], \"entity_id\": [\"T13\", \"T14\"]}}]}}"
}
]
}
] |
11142491_2 | We describe the exceptional development of AML and lung cancer in a patient with previously diagnosed CLL in minimal residual disease status after fludarabine treatment followed by autologous peripheral blood stem-cell transplantation. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"development\"]], \"start\": [[28]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"fludarabine\", \"autologous peripheral blood stem-cell transplantation\"]], \"start\": [[147, 181]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"CLL in minimal residual disease status\"]], \"start\": [[102]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"fludarabine\"], [\"autologous peripheral blood stem-cell\"]], \"start\": [[147], [181]], \"entity_id\": [\"T11\", \"T12\"]}, \"Route\": {\"text\": [[\"transplantation\"]], \"start\": [[219]], \"entity_id\": [\"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"followed by\"]], \"start\": [[169]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"fludarabine\"], [\"autologous peripheral blood stem-cell\"]], \"start\": [[147], [181]], \"entity_id\": [\"T11\", \"T12\"]}}]}, \"Effect\": {\"text\": [[\"AML\", \"lung cancer\"]], \"start\": [[43, 51]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"a patient with previously diagnosed CLL in minimal residual disease status\"]], \"start\": [[66]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
12095907_2 | Valproate-induced hyperammonemia as a cause of altered mental status. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[10]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Valproate\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Valproate\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"altered mental status\", \"hyperammonemia\"]], \"start\": [[47, 18]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
6353252_3 | We report 5 cases of acute reversible renal failure coinciding with the onset of treatment with captopril in patients with severe drug-resistant hypertension. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"onset of treatment\"]], \"start\": [[72]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"captopril\"]], \"start\": [[96]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"captopril\"]], \"start\": [[96]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"severe drug-resistant hypertension\"]], \"start\": [[123]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"patients with severe drug-resistant hypertension\"]], \"start\": [[109]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"acute reversible renal failure\"]], \"start\": [[21]], \"entity_id\": [\"T3\"]}, \"Severity\": {\"text\": [[\"acute\"]], \"start\": [[21]], \"entity_id\": [\"T11\"], \"value\": \"High\"}}"
}
]
}
] |
9375469_3 | We report a case of contact dermatitis due to sodium bisulfite in Tathion eye drops. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[39]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"contact dermatitis\"]], \"start\": [[20]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"sodium bisulfite\"]], \"start\": [[46]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"sodium bisulfite\"]], \"start\": [[46]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
19815480_1 | The first patient is undergoing hemodialysis and, though responding to sunitinib, is having significant fatigue and hypertension. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"having\"]], \"start\": [[85]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"sunitinib\"]], \"start\": [[71]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"sunitinib\"]], \"start\": [[71]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"The first patient\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"significant fatigue and hypertension\"]], \"start\": [[92]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
17536204_4 | CCBs should be considered in the treatment of 5-FU or capecitabine-induced headaches. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[33]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"CCBs\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"CCBs\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"headaches\"]], \"start\": [[75]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
9337441_8 | Furosemide, spironolactone, allopurinol, and hydroxyurea were considered possible causes of the reaction and were discontinued. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"causes\"]], \"start\": [[82]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"Furosemide, spironolactone, allopurinol, and hydroxyurea\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"Furosemide\"], [\"spironolactone\"], [\"allopurinol\"], [\"hydroxyurea\"]], \"start\": [[0], [12], [28], [45]], \"entity_id\": [\"T10\", \"T11\", \"T12\", \"T13\"]}}, \"Effect\": {\"text\": [[\"reaction\"]], \"start\": [[96]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
11414270_5 | PATIENTS: One patient with mucositis secondary to chemotherapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"secondary\"]], \"start\": [[37]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"chemotherapy\"]], \"start\": [[50]], \"entity_id\": [\"T6\"], \"Route\": {\"text\": [[\"chemotherapy\"]], \"start\": [[50]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"mucositis\"]], \"start\": [[27]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"One patient\"]], \"start\": [[10]], \"entity_id\": [\"T8\"], \"Population\": {\"text\": [[\"One\"]], \"start\": [[10]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
15266150_1 | A patient with monocular open-angle glaucoma had trichiasis, a condition associated with the use of a prostaglandin analog. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"had\"]], \"start\": [[45]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"A patient with monocular open-angle glaucoma\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"trichiasis\"]], \"start\": [[49]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"a prostaglandin analog\"]], \"start\": [[100]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"monocular open-angle glaucoma\"]], \"start\": [[15]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"prostaglandin analog\"]], \"start\": [[102]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
21189363_3 | A 53-year-old African American male with HIV was prescribed warfarin 5 mg/day for 12 months after diagnosis of idiopathic deep vein thrombosis and bilateral pulmonary emboli (target INR 2.5 [range 2.0-3.0]). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"prescribed\"]], \"start\": [[49]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"A 53-year-old African American male with HIV\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Age\": {\"text\": [[\"53-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T11\"]}, \"Race\": {\"text\": [[\"African American\"]], \"start\": [[14]], \"entity_id\": [\"T12\"]}, \"Gender\": {\"text\": [[\"male\"]], \"start\": [[31]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"HIV\"]], \"start\": [[41]], \"entity_id\": [\"T14\"]}}, \"Treatment\": {\"text\": [[\"warfarin 5 mg/day for 12 months\"]], \"start\": [[60]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"warfarin\"]], \"start\": [[60]], \"entity_id\": [\"T15\"]}, \"Dosage\": {\"text\": [[\"5 mg/day\"]], \"start\": [[69]], \"entity_id\": [\"T16\"]}, \"Duration\": {\"text\": [[\"12 months\"]], \"start\": [[82]], \"entity_id\": [\"T18\"]}, \"Disorder\": {\"text\": [[\"idiopathic deep vein thrombosis and bilateral pulmonary emboli\"]], \"start\": [[111]], \"entity_id\": [\"T19\"]}}}"
}
]
}
] |
18836269_1 | After treatment with a beta-sympathomimetic drug (Partusisten) one fetus developed supraventricular tachycardia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[73]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"a beta-sympathomimetic drug (Partusisten)\"]], \"start\": [[21]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Partusisten\"]], \"start\": [[50]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"one fetus\"]], \"start\": [[63]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"fetus\"]], \"start\": [[67]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"supraventricular tachycardia.\"]], \"start\": [[83]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
17189581_16 | Serotonin syndrome developed in a patient taking concurrent linezolid and fluoxetine. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[19]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[32]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"concurrent linezolid and fluoxetine\"]], \"start\": [[49]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"linezolid\"], [\"fluoxetine\"]], \"start\": [[60], [74]], \"entity_id\": [\"T11\", \"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"concurrent\"]], \"start\": [[49]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"linezolid\"], [\"fluoxetine\"]], \"start\": [[60], [74]], \"entity_id\": [\"T11\", \"T12\"]}}]}, \"Effect\": {\"text\": [[\"Serotonin syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
18533420_2 | RESULTS: A male and a female patient with spasticity treated with intrathecal baclofen were recognized to have sexual dysfunction side effects from treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[53]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"A male and a female patient with spasticity\"]], \"start\": [[9]], \"entity_id\": [\"T3\"], \"Gender\": {\"text\": [[\"male\"], [\"female\"]], \"start\": [[11], [22]], \"entity_id\": [\"T8\", \"T9\"]}}, \"Treatment\": {\"text\": [[\"intrathecal baclofen\"]], \"start\": [[66]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"spasticity\"]], \"start\": [[42]], \"entity_id\": [\"T4\"]}, \"Drug\": {\"text\": [[\"baclofen\"]], \"start\": [[78]], \"entity_id\": [\"T10\"]}, \"Route\": {\"text\": [[\"intrathecal\"]], \"start\": [[66]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"sexual dysfunction\"]], \"start\": [[111]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
8672829_5 | OBJECTIVE: To describe a patient with ifosfamide-induced nonconvulsive status epilepticus. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[49]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"patient\"]], \"start\": [[25]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"ifosfamide\"]], \"start\": [[38]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"ifosfamide\"]], \"start\": [[38]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"nonconvulsive status epilepticus\"]], \"start\": [[57]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
18252776_1 | Upper gastrointestinal haemorrhage is a serious complication of aspirin and clopidogrel (dual) anti-platelet therapy with a high morbidity and mortality. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complication\"]], \"start\": [[48]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Upper gastrointestinal haemorrhage\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"aspirin and clopidogrel (dual)\"]], \"start\": [[64]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
17448102_2 | Flecainide overdose can rapidly result in profound cardiovascular collapse, and is associated with a relatively high mortality. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"result\"]], \"start\": [[32]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"Flecainide overdose\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"Flecainide\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}, \"Dosage\": {\"text\": [[\"overdose\"]], \"start\": [[11]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"profound cardiovascular collapse, and is associated with a relatively high mortality\"]], \"start\": [[42]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
2894766_4 | Sulfasalazine-induced lupus erythematosus. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[14]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Sulfasalazine\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Sulfasalazine\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"lupus erythematosus\"]], \"start\": [[22]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
4036917_2 | Reye syndrome (RS) is believed to occur infrequently among children receiving long-term aspirin therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occur\"]], \"start\": [[34]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"Reye syndrome (RS)\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"long-term aspirin\"]], \"start\": [[78]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"aspirin\"]], \"start\": [[88]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"children\"]], \"start\": [[59]], \"entity_id\": [\"T7\"], \"Age\": {\"text\": [[\"children\"]], \"start\": [[59]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
14746605_2 | Propecia-associated bilateral cataract. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[9]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Propecia\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Propecia\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"bilateral cataract\"]], \"start\": [[20]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
12921505_1 | After 39 hours on argatroban, the infusion was stopped when minor bleeding was observed with a concurrent activated partial thromboplastin time (aPTT) of 100 seconds. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"After\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"argatroban\"]], \"start\": [[18]], \"entity_id\": [\"T3\"], \"Time_elapsed\": {\"text\": [[\"39 hours\"]], \"start\": [[6]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"argatroban\"]], \"start\": [[18]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"minor bleeding was observed with a concurrent activated partial thromboplastin time (aPTT) of 100 seconds\"]], \"start\": [[60]], \"entity_id\": [\"T4\"]}, \"Severity\": {\"text\": [[\"minor\"]], \"start\": [[60]], \"entity_id\": [\"T8\"], \"value\": \"Low\"}}"
}
]
}
] |
6540393_2 | Anaphylactoid reaction to methylprednisolone pulsed therapy for multiple sclerosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"to\"]], \"start\": [[23]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"methylprednisolone pulsed therapy\"]], \"start\": [[26]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"multiple sclerosis\"]], \"start\": [[64]], \"entity_id\": [\"T4\"]}, \"Drug\": {\"text\": [[\"methylprednisolone\"]], \"start\": [[26]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Anaphylactoid reaction\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
17044380_2 | Warfarin-induced skin necrosis and heparin-induced thrombocytopenia following mitral valve replacement for marantic endocarditis. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[9]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"Warfarin\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"Warfarin\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"skin necrosis\"]], \"start\": [[17]], \"entity_id\": [\"T6\"]}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[43]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"heparin\"]], \"start\": [[35]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"marantic endocarditis\"]], \"start\": [[107]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"heparin\"]], \"start\": [[35]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"thrombocytopenia\"]], \"start\": [[51]], \"entity_id\": [\"T13\"]}}"
}
]
}
] |
18020545_1 | Surprisingly, we found that three patients appeared to develop tardive OGC while taking clozapine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"develop\"]], \"start\": [[55]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"tardive OGC\"]], \"start\": [[63]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"clozapine\"]], \"start\": [[88]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"clozapine\"]], \"start\": [[88]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"three patients\"]], \"start\": [[28]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"three\"]], \"start\": [[28]], \"entity_id\": [\"T7\"]}}, \"Speculated\": {\"text\": [[\"appeared\"]], \"start\": [[43]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
11207969_4 | We report a fatal case of toxic epidermal necrolysis (TEN) resulting from a high dose of cytosine arabinoside (ARA-C). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"resulting from\"]], \"start\": [[59]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"toxic epidermal necrolysis (TEN)\"]], \"start\": [[26]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"high dose of cytosine arabinoside (ARA-C)\"]], \"start\": [[76]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"cytosine arabinoside (ARA-C)\"]], \"start\": [[89]], \"entity_id\": [\"T10\"]}, \"Dosage\": {\"text\": [[\"high dose\"]], \"start\": [[76]], \"entity_id\": [\"T11\"]}}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[12]], \"entity_id\": [\"T12\"], \"value\": \"High\"}}"
}
]
}
] |
11207969_2 | On the fifth day after administration of a high dose of ARA-C (2 g/m2 intravenously every 12 hours), she developed bullous lesions on the hands and soles that disseminated, evolving to necrosis, sepsis, and death on the 22nd day. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[105]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"high dose of ARA-C\"]], \"start\": [[43]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"ARA-C\"]], \"start\": [[56]], \"entity_id\": [\"T10\"]}, \"Dosage\": {\"text\": [[\"high dose\"], [\"2 g/m2\"]], \"start\": [[43], [63]], \"entity_id\": [\"T11\", \"T13\"]}, \"Time_elapsed\": {\"text\": [[\"the fifth day\"], [\"the 22nd day\"]], \"start\": [[3], [216]], \"entity_id\": [\"T12\", \"T15\"]}, \"Freq\": {\"text\": [[\"12 hours\"]], \"start\": [[90]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"bullous lesions on the hands and soles that disseminated, evolving to necrosis, sepsis, and death\"]], \"start\": [[115]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
8730143_3 | We describe 2 patients with cutaneous lupus erythematosus who developed severe dapsone reaction after low dose therapy, with a fatal outcome in one. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[96]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"2 patients with cutaneous lupus erythematosus\"]], \"start\": [[12]], \"entity_id\": [\"T5\"], \"Population\": {\"text\": [[\"2\"]], \"start\": [[12]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"low dose therapy\"]], \"start\": [[102]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"cutaneous lupus erythematosus\"]], \"start\": [[28]], \"entity_id\": [\"T10\"]}, \"Dosage\": {\"text\": [[\"low dose\"]], \"start\": [[102]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"dapsone\"]], \"start\": [[79]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"severe dapsone reaction\", \"with a fatal outcome in one\"]], \"start\": [[72, 120]], \"entity_id\": [\"T8\"]}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[127]], \"entity_id\": [\"T11\"], \"value\": \"High\"}}"
}
]
}
] |
1359782_1 | A patient with ulcerative colitis developed skin pigmentation and diffuse pulmonary shadowing without respiratory symptomatology, while taking sulfasalazine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[34]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"sulfasalazine\"]], \"start\": [[143]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"sulfasalazine\"]], \"start\": [[143]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"ulcerative colitis\"]], \"start\": [[15]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"A patient with ulcerative colitis\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"skin pigmentation and diffuse pulmonary shadowing without respiratory symptomatology\"]], \"start\": [[44]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |